Neosoma Brain Mets
Overview
Neosoma Brain Mets is an FDA-cleared AI-powered software medical device designed for the rapid MRI assessment and accurate, consistent analysis of brain metastases. It provides novel tumor insights to physicians and researchers in near-real-time, supporting radiology, radiation oncology, medical oncology, and surgical workflows, as well as tumor board decision-making. The technology identifies lesions as small as 1mm3 isotropic and can track any number of identified lesions over time. It operates on routinely-acquired T1 post-contrast sequences, requiring no special acquisition protocols. Neosoma Brain Mets auto-contours target (GTV) volumes and integrates seamlessly into radiation oncology and surgical planning software such as Eclipse, MIM, Brainlab, Gamma Plan, and Stealth. The platform is cloud-based, web-based, PACS-integrated, and offers an intuitive interface with interactive charts, 3D/2D visualizations, and smart segmentation/contour editing tools to expedite clinical case review. It is intended for use by qualified and trained medical professionals for informational purposes and not to replace manual contouring or detect tumors for diagnosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Rapid MRI assessment and analysis
- Accurate and consistent lesion identification (as small as 1mm3 isotropic)
- Near-real-time study processing
- Longitudinal tracking of brain lesions over time
- Operates on routinely-acquired T1 post-contrast sequences
- Automated Gross Tumor Volume (GTV) contouring
- Interoperability with radiation treatment and surgical planning software (e.g., Eclipse, MIM, Brainlab, Gamma Plan, Stealth)
- Cloud-based, web-based, and PACS-integrated platform
- Interactive charts, 3D/2D visualizations, and smart segmentation/contour editing tools
- MRI protocol tolerant (no changes to acquisition protocols needed)
- Reimbursable (Available Category 3 CPT Codes: 0865T, 0866T)
Use Cases
- Assessment of brain metastases
- Longitudinal tracking of brain lesions
- Radiation treatment planning (GTV contouring)
- Surgical planning
- Tumor board decision-making
- Clinical research and trials
What Physicians Need to Know
Neosoma Brain Mets is a valuable tool for expediting the assessment and auto-contouring of metastatic brain lesions, particularly for radiation treatment planning and surgical planning. It provides detailed quantitative information on individual lesions and total tumor burden over time, which can be crucial for monitoring treatment response and making informed decisions in multidisciplinary tumor boards. Remember that the software is intended to assist and not replace the clinician's judgment or manual contouring, and medical professionals must finalize the generated contours. The technology operates on routinely-acquired T1 post-contrast MRI sequences, eliminating the need for special acquisition protocols.
Neosoma Brain Mets is fully integrated with Neosoma's proprietary cloud platform. It integrates directly into PACS workflows, supporting automated sending of DICOM studies for analysis and offering one-click deep linking from PACS to the Neosoma system. The software is interoperable with radiation treatment and surgical planning software, allowing easy import of lesion contours (GTVs) into systems such as Eclipse, MIM, Brainlab, Gamma Plan, and Stealth. Neosoma also has a distribution partnership with Microsoft's Nuance division.
Details
| Category | Neurology AI, Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurosurgery, Oncology, Radiology |
What the Web Says
Neosoma Brain Mets is an AI-based software designed to assist healthcare professionals in the detection, tracking, and treatment planning of brain metastases. It has received FDA 510(k) clearance and is integrated into Neosoma's cloud platform. The software automates lesion identification, volumetric measurement, and radiation therapy contouring from standard MRI scans, aiming to expedite assessments and enhance decision-making in neuro-oncology workflows.
Overall: PositiveStrengths
- Automates lesion identification, volumetric measurement, and radiation therapy contouring, saving time and effort for clinicians.
- Provides rapid MRI assessment and accurate, consistent analysis with near-real-time study processing.
- Capable of identifying, contouring, and tracking an unlimited number of individual lesions, even those as small as 1mm³ isotropic.
- Integrates seamlessly into radiation oncology and surgical planning software.
- Operates on routinely-acquired T1 post-contrast MRI sequences, requiring no special acquisition protocols.
- Supports multidisciplinary team collaboration across radiology, radiation oncology, medical oncology, and surgical workflows, as well as tumor board decision-making.
Limitations
- Not intended to replace the clinician's current standard practice of manual contouring or to detect tumors for primary diagnosis.
- Specifically designed for adult patients (age 22 and older) and not intended for use with images representing other types of brain lesions.
- Medical professionals must finalize (confirm or modify) the contours generated by the software.
- Limited information available from independent tech reviewers, G2, Capterra, or extensive Reddit discussions directly about the product, with Reddit discussions primarily focusing on personal experiences with brain metastases rather than the software itself.
Based on reviews from: alcancercongress.org, fda.gov, neosomainc.com, inspire.com, beckershospitalreview.com, beckersoncology.com, diagnosticimaging.com, reddit.com, innolitics.com, businesswire.com, nih.gov
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neosoma Brain Mets
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Neosoma Brain Mets.
Ken Kolodziej, Founder & CEO of Neosoma.
Frequently Asked Questions
Investors who backed Neosoma Brain Mets
Funded through the company that built this tool.
